Company Overview of Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the infectious disease field in the United States. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection. The company also develops Bicyclolide antibiotic products focuses on mechanisms gram-positive pathogens, including bacteria resistant...
500 Arsenal Street
Watertown, MA 02472
Founded in 1995
Key Executives for Enanta Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $751.8K
Chief Financial Officer and Senior Vice President of Finance & Administration
Total Annual Compensation: $440.3K
Chief Scientific Officer and Senior Vice President of Research & Development
Total Annual Compensation: $514.1K
Compensation as of Fiscal Year 2014.
Enanta Pharmaceuticals, Inc. Key Developments
Enanta Pharmaceuticals, Inc. Announces New Data from AbbVie’s Phase 3 Gift-I Study
May 26 15
Enanta Pharmaceuticals, Inc. announced that new data from AbbVie’s phase 3 GIFT-I study, its investigational, all-oral, interferon (IFN)- and ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir, was presented at the Annual Meeting of the Japan Society of Hepatology in Kumamoto, Japan. GIFT-I evaluated genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected Japanese patients, with and without cirrhosis, who were either treatment-naïve or Interferon (with or without RBV) treatment-experienced. The primary endpoint was achieved, demonstrating 95% (n=106/112) SVR12 in a sub-group of treatment-naïve, non-cirrhotic, adult GT1b HCV infected Japanese patients who were eligible for therapy with IFN and had a high viral load.1 In study results related to the secondary endpoint, GT1b HCV patients with compensated cirrhosis achieved 91% (n=38/42) SVR12. In an additional intent-to-treat (ITT) analysis, SVR12 was achieved in 98% (n=104/106) of the GT1b HCV infected patients without cirrhosis (Arm B) who were randomized to initially receive double-blind placebo for 12 weeks, followed by open-label treatment with ombitasvir/paritaprevir/ritonavir. The ITT population included every patient that was randomized to placebo and received at least one dose of active, open-label study drug. Across all study arms, three patients (n=3/363) discontinued treatment due to adverse events. The most commonly reported adverse events (>5% in any arm) were nasopharyngitis, headache, peripheral edema, nausea, pyrexia and decreased platelet count.
Enanta Pharmaceuticals, Inc. Announces Consolidated Earnings for the Second Quarter and Six Months Ended March 31, 2015; Provides Royalties Guidance for the Third Quarter Ending June 30, 2015
May 7 15
Enanta Pharmaceuticals, Inc. announced consolidated earnings for the second quarter and six months ended march 31, 2015. For the quarter, the company reported revenue was $57.4 million, compared to $2.2 million for the three months ended March 31, 2014. The increase in revenue for the most recent quarter was primarily due to the achievement of a $50.0 million milestone payable from AbbVie for the European regulatory approval of VIEKIRAX as well as $7.0 million in royalty revenue, which was earned from a contractually specified portion of AbbVie’s worldwide net sales of HCV treatment regimens containing paritaprevir, Enanta’s lead hepatitis C virus (HCV) protease inhibitor identified within the ongoing AbbVie-Enanta collaboration. Net income was $28.8 million, or $1.49 per diluted common share, compared to a net loss of $5.2 million, or $0.28 per diluted common share, for the corresponding period in 2014. The increase in net income during the three months ended March 31, 2015 was primarily due to milestone payments and royalty revenue earned and payable from AbbVie. Income from operations was $48.561 million against loss from operations of $5.127 million a year ago. Income before income taxes was $48.771 million against loss before income taxes of $5.203 million a year ago.
For the six months ended March 31, 2015, revenue was $134.9 million, compared to revenue of $3.1 million for the same period in 2014. The increase in revenue for the six months ended March 31, 2015 was due to the achievement of a $75.0 million milestone payment as a result of U.S. regulatory approval of Viekira Pak, in addition to the $50.0 million milestone and royalties earned on paritaprevir. Milestone payments, royalties and other payments from collaborations have varied significantly from period to period, and are expected to continue to do so. Net income was $70.8 million, or $3.67 per diluted common share, compared to a net loss of $10.6 million, or $0.58 per diluted common share for the same period in 2014. The increase in net income during six month period ended March 31, 2015 was primarily due to milestone payments and royalty revenue earned and payable from AbbVie. Income from operations was $118.771 million against loss from operations of $10.584 million a year ago. Income before income taxes was $119.282 million against loss before income taxes of $10.573 million a year ago.
For the third quarter ending June 30, 2015, the company expects royalties to Enanta would continue to be approximately 3% of such sales.
Enanta Pharmaceuticals, Inc. to Report Q2, 2015 Results on May 07, 2015
Apr 27 15
Enanta Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 9:00 AM, Eastern Standard Time on May 07, 2015
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|